- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00667121
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline
The Effect of Antidepressants and Gabapentin on Tamoxifen Pharmacokinetics: A Prospective Study
RATIONALE: Studying samples of blood in the laboratory from patients receiving tamoxifen may help doctors learn more about the effects of other drugs on the level of tamoxifen in the blood.
PURPOSE: This clinical trial is studying levels of tamoxifen in the blood of women with breast cancer and in women at high risk of breast cancer who are receiving tamoxifen together with venlafaxine, citalopram, escitalopram, gabapentin, or sertraline.
Study Overview
Status
Intervention / Treatment
- Other: pharmacological study
- Other: laboratory biomarker analysis
- Other: high performance liquid chromatography
- Procedure: adjuvant therapy
- Drug: tamoxifen citrate
- Drug: citalopram hydrobromide
- Drug: gabapentin
- Genetic: molecular genetic technique
- Drug: escitalopram oxalate
- Drug: sertraline hydrochloride
- Drug: venlafaxine
Detailed Description
OBJECTIVES:
- To examine the changes in the plasma concentrations of the hydroxylated metabolite, 4-hydroxy tamoxifen, and endoxifen in women with known or at high risk for developing breast cancer who are receiving selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor therapy comprising venlafaxine, citalopram hydrobromide, escitalopram oxalate, gabapentin, or sertraline hydrochloride for the treatment of hot flashes, depression, or any other medically indicated condition.
- To evaluate whether genetic variants known to affect the activity of CYP2D6, SULT1A1, and other drug metabolizing enzymes (e.g., UGT's) involved in the biotransformation of tamoxifen citrate affect the plasma concentrations of the hydroxylated metabolites, 4-hydroxy tamoxifen and endoxifen.
OUTLINE: This is a multicenter study.
Patients receive oral tamoxifen citrate and concurrent selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) therapy comprising oral venlafaxine, citalopram hydrobromide, escitalopram oxalate, sertraline hydrochloride, or gabapentin for 8-24 weeks. Treatment continues in the absence of disease progression.
Blood samples are obtained at baseline and after completion of study therapy. Samples are evaluated by pharmacokinetic analysis to determine the effects of SSRI/SNRI study drugs on plasma concentrations of tamoxifen and its metabolites. Plasma levels of tamoxifen citrate, N-desmethyl tamoxifen, 4-OH tamoxifen, and endoxifen are measured using reverse phase high performance liquid chromatography. Blood samples are also analyzed by CYP2D6 genotyping to test for CYP2D6 gene variation (i.e., *3, *4, *6, *10, *17, and *41) in genes that encode tamoxifen-metabolizing enzymes. Additional CYP2D6 alleles, including gene duplication and gene deletion (*5) are assessed.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-5289
- Indiana University Melvin and Bren Simon Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21231-2410
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0942
- University Of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- UNC Lineberger Comprehensive Cancer Center
-
-
Virginia
-
Arlington, Virginia, United States, 22205
- Virginia Cancer Specialists PC-Arlington
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- Life expectancy ≥ 16 weeks
- No contraindication for venlafaxine, citalopram hydrobromide, escitalopram oxalate, gabapentin, or sertraline hydrochloride
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 4 weeks since prior and no concurrent medications that are known to inhibit the CYP2D6 system
Description
Inclusion Criteria:
- Prescribed tamoxifen either for the prevention or treatment of non-invasive or invasive breast cancer.
- Tamoxifen use > 4 weeks without any breaks at a dose of 20 mg/day prior to registration
- to begin medical therapy with one of the following drugs: venlafaxine, citalopram, escitalopram, sertraline or gabapentin as determined by their physician
- Agree to continue tamoxifen during the proposed minimum study period of 8 weeks
- Willing to avoid known inhibitors of the CYP2D6 system for duration of study
- Ability to provide informed consent
- Willing to return to primary site of enrollment for follow-up
- Life expectancy >= 16 weeks
- Agree to provide a blood specimen at the time of pre-treatment (baseline) and at follow-up
Exclusion Criteria:
- Contraindication to the use of venlafaxine, citalopram, escitalopram, gabapentin or sertraline.
- Use of medications that are known to inhibit the CYP2D6 system within 3 weeks of registration. (see appendix II for list)
Known to be a CYP2D6 poor metabolizer (defined as homozygous for one of the following CYP2D6 null alleles: *3, *4, *5, *6).
- Note: CYP2D6 genotyping is not required prior to enrollment; however, CYP2D6 genotyping will be performed at baseline and the treating physician will be notified of the results: all genotypic CYP2D6 PM will be replaced
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent change in plasma concentrations of 4-hydroxy tamoxifen and of endoxifen after ≥ 8 weeks of concurrent administration of tamoxifen citrate and a CYP2D6 inhibitor
Time Frame: Between 8-16 weeks
|
Between 8-16 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Matthew P. Goetz, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Behavioral Symptoms
- Skin Diseases
- Breast Diseases
- Depression
- Breast Neoplasms
- Hot Flashes
- Serotonin and Noradrenaline Reuptake Inhibitors
- Antineoplastic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Central Nervous System Depressants
- Sensory System Agents
- Bone Density Conservation Agents
- Analgesics
- Neurotransmitter Agents
- Membrane Transport Modulators
- Anti-Anxiety Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Hormone Antagonists
- Neurotransmitter Uptake Inhibitors
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Antidepressive Agents
- Anticonvulsants
- Serotonin Agents
- Antimanic Agents
- Excitatory Amino Acid Agents
- Excitatory Amino Acid Antagonists
- Estrogen Antagonists
- Selective Serotonin Reuptake Inhibitors
- Antidepressive Agents, Second-Generation
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Parasympatholytics
- Gabapentin
- Venlafaxine Hydrochloride
- Escitalopram
- Tamoxifen
- Citalopram
- Sertraline
- Dexetimide
Other Study ID Numbers
- MC0738 (Mayo Clinic Cancer Center)
- 07-006133 (Other Identifier: Mayo Clinic IRB)
- NCI-2011-00406 (Registry Identifier: NCI CTRP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.